PremiumThe FlyMorning Movers: UnitedHealth sinks following CEO exit and outlook suspension Altimmune secures up to $100M in credit facility Altimmune Secures $100 Million Credit Facility PremiumRatingsAltimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing Altimmune’s Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets Altimmune’s Pemvidutide: A Promising Best-in-Class Therapy with Broad Potential and Strong Buy Rating PremiumThe FlyEvercore bullish on Altimmune, likes drug move into alcohol related disease Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook Altimmune’s Pemvidutide: Promising Future with IMPACT Trial and Market Expansion 
